Our AAVneO system uses in-vivo direct evolution and high-throughput screening to discover the next-generation adeno-associated viral vectors with enhanced targeting ability, improved payload size, lower immunogenicity, and superior manufacturability. AAVneo will serve as an integrated platform that enables gene therapy developersto screen, select, and co-develop the next-generation vectors for a broad range of diseases and overcome the limitations of conventional AAV-based gene therapies.